An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation

Abstract

BackgroundRHEB is a unique member of the RAS superfamily of small GTPases expressed in all tissues and conserved from yeast to humans. Early studies on RHEB indicated a possible RHEB-RAF interaction, but this has not been fully explored. Recent work on cancer genome databases has revealed a reoccurring mutation in RHEB at the Tyr35 position, and a recent study points to the oncogenic potential of this mutant that involves activation of RAF/MEK/ERK signaling. These developments prompted us to reassess the significance of RHEB effect on RAF, and to compare mutant and wild type RHEB.MethodsTo study RHEB-RAF interaction, and the effect of the Y35N mutation on this interaction, we used transfection, immunoprecipitation, and Western blotting techniques. We generated cell lines stably expressing RHEB WT, RHEB Y35N, and KRAS G12V, and monitored cellular transforming properties through cell proliferation, anchorage independent growth, cell cycle analysis, and foci formation assays.ResultsWe observe a strong interaction between RHEB and BRAF, but not with CRAF. This interaction is dependent on an intact RHEB effector domain and RHEB-GTP loading status. RHEB overexpression decreases RAF activation of the RAF/MEK/ERK pathway and RHEB knockdown results in an increase in RAF/MEK/ERK activation. RHEB Y35N mutation has decreased interaction with BRAF, and RHEB Y35N cells exhibit greater BRAF/CRAF heterodimerization resulting in increased RAF/MEK/ERK signaling. This leads to cancer transformation of RHEB Y35N stably expressing cell lines, similar to KRAS G12 V expressing cell lines.ConclusionsRHEB interaction with BRAF is crucial for inhibiting RAF/MEK/ERK signaling. The RHEB Y35N mutant sustains RAF/MEK/ERK signaling due to a decreased interaction with BRAF, leading to increased BRAF/CRAF heterodimerization. RHEB Y35N expressing cells undergo cancer transformation due to decreased interaction between RHEB and BRAF resulting in overactive RAF/MEK/ERK signaling. Taken together with the previously established function of RHEB to activate mTORC1 signaling, it appears that RHEB performs a dual function; one is to suppress the RAF/MEK/ERK signaling and the other is to activate mTORC1 signaling.Electronic supplementary materialThe online version of this article (10.1186/s12885-017-3938-5) contains supplementary material, which is available to authorized users.

Unraveling the Role of Ras Homolog Enriched in Brain (Rheb1 and Rheb2): Bridging Neuronal Dynamics and Cancer Pathogenesis through Mechanistic Target of Rapamycin Signaling

“…Rheb1's role in cancer is intricate, impacting cell growth and apoptosis, albeit the precise mechanisms remain unclear [160,182]. It influences apoptosis via mTORC1 and independently, particularly through its interaction with FKBP38, Bcl-2, and Bcl-XL [183].…”

A comprehensive analysis of RAS-effector interactions reveals interaction hotspots and new binding partners

“…As the RB domains of the RAF paralogs are conserved (33), mainly regarding their RAS binding residues (Fig. S3 (61). They have shown that a variant of RHEB (Y35 to asparagine; Y32 in HRAS) impedes RHEB interaction with BRAF leading to an increased BRAF/CRAF heterodimerization and thus activation of the MAPK pathway.…”

“…They have shown that a variant of RHEB (Y35 to asparagine; Y32 in HRAS) impedes RHEB interaction with BRAF leading to an increased BRAF/CRAF heterodimerization and thus activation of the MAPK pathway. Accordingly, they have proposed a dual function for RHEB, suppression of the MAPK pathway and mTORC1 activation (61).…”

Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy

“…Yield 36%, m.p. 240-242 (20) To a solution of 2-amino-5-chloronicotinamide 19 (34.97 mmol) in 1,4-dioxane (30 mL) was added diphosgene (111.90 mmol), then the mixture was charged with N 2 and stirred at 120 • C for 12 h. After completion (monitored by TLC), cooled to r.t. Dry diethyl ether (100 mL) was added and stirred at r.t for 1 h, the precipitation separated out. Suction and drying to give a brown solid.…”

“…Phosphorylated PI3K could activate RAS via several mechanisms [18], thereby reactivating the ERK pathway. Meanwhile, inhibition of PDK1, AKT or Rheb could increase RAF activities [19][20][21]. Besides, the classic feedback loop (S6-IRS1-PI3K) leads to activation of PI3K but also ERK signaling [22].…”